相关临床试验
0
0 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
N/A
暂无试验阶段数据
暂无试验数据
暂无试验数据
暂无批准数据
- Penn Medicine, founded in 1751, has launched a national brand campaign titled "First Then, First Now" to mark its 275th anniversary and America's approaching 250th birthday. - The campaign, developed with agency Yard NYC, draws from archival materials including handwritten letters, surgical sketches, and research journals to create a "living scrapbook" of medical breakthroughs. - Key milestones highlighted include the nation's first hospital and medical school, the first maternity ward, the first X-ray image, mRNA vaccine technology, and CAR T cell therapy. - The multi-channel campaign runs through August across broadcast, digital, out-of-home, print, search, and audio in Philadelphia and key national markets including Boston, Chicago, Los Angeles, New York, and San Francisco.
- Five-year follow-up data from the phase 3 KEYNOTE-564 study demonstrate that adjuvant pembrolizumab continues to improve disease-free survival and overall survival compared to placebo in patients with clear cell renal cell carcinoma at increased risk of recurrence. - The immunotherapy showed consistent benefits across all prespecified subgroups, including varying risk categories and patients with sarcomatoid features, with median disease-free survival not reached versus 68.3 months with placebo. - Real-world data from the ARON-1 study confirm pembrolizumab's effectiveness in clinical practice, with 2-year overall survival and disease-free survival rates of 95% and 69%, respectively. - Long-term safety profile remains stable with no new serious toxicities emerging beyond three years of treatment.
- Fixed-duration cevostamab consolidation following BCMA-directed CAR-T cell therapy demonstrated feasibility and tolerability in heavily pretreated multiple myeloma patients, with a 93% MRD-negative complete response rate at one year. - The phase 2 STEM trial enrolled 27 patients who received cevostamab for 8 cycles after standard CAR-T therapy, showing improved response rates from 63% pre-treatment to 93% at one-year follow-up. - Safety profile was manageable with predominantly hematologic adverse events, while over 90% of evaluable patients sustained MRD-negative complete responses at one year post-CAR-T therapy.
- A University of Pennsylvania study demonstrated that embedding infectious disease screening within inpatient substance use disorder treatment programs increased screening rates from 6.1% to 90.3% for hepatitis A and similar dramatic improvements for other infections. - The intervention involved an infectious disease-trained nurse navigator who guided patients through HIV and hepatitis testing, obtained STI and tuberculosis exposure history, and offered prophylaxis and treatment as appropriate. - Vaccination rates improved significantly, with hepatitis A vaccination rising from 0% to 58% and hepatitis B vaccination from 0% to 71% in the intervention group. - The comprehensive approach facilitated prompt delivery of preventive services and treatment, addressing healthcare barriers in a stigmatized patient population with increased infectious disease risk.
- Openwater's Open-Motion device demonstrated 79% accuracy in identifying large vessel occlusion strokes and 84% accuracy in excluding non-LVO cases in prehospital settings. - The portable cerebral blood flow monitor allows emergency medical services teams to optimize stroke triage by adapting diagnostic settings for sensitivity or specificity based on local needs. - University of Birmingham becomes the first institution to receive the latest Open-Motion version for clinical trials studying stroke rehabilitation and movement recovery. - The device uses near-infrared light to track blood flow and blood volume, offering potential for democratizing advanced neurological diagnostics through its open-source, affordable platform.
